Tiziana Life Sciences Ltd. (TLSA), a London-based biotechnology company, Thursday announced it does not plan to pursue capital-raising activities in the proximate future.
Building on yesterday's announcement of discovering new immune biomarkers in non-active secondary progressive multiple sclerosis widely known as "na-SPMS" patients treated with nasal foralumab, the Company has decided not to pursue capital-raising activities in the near term.
TLSA is currently trading at $0.7140 or 10.4028% lower on the Nasdaq Capital Market.
For comments and feedback: editorial@rttnews.com